Does Rallies show Form 4 insider transactions for APGE?

Yes. Rallies tracks APGE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is APGE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for APGE. It does not provide personalized investment advice.

APGE (Apogee Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Apogee Therapeutics, Inc. Common Stock (APGE) is a publicly traded Healthcare sector company. As of May 21, 2026, APGE trades at $81.49 with a market cap of $5.94B and a P/E ratio of -19.12. APGE moved +4.09% today. Year to date, APGE is +5.01%; over the trailing twelve months it is +101.76%. Its 52-week range spans $26.20 to $95.32. Analyst consensus is strong buy with an average price target of $122.25. Rallies surfaces APGE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading APGE stock inside the company?

Recent APGE insider activity includes HENDERSON MICHAEL THOMAS sold 18.66K, HENDERSON MICHAEL THOMAS sold 1.34K, Dambkowski Carl sold 3.70K, Dambkowski Carl sold 1.80K, and Henderson Jane sold 811. Rallies tracks insider transaction dates, shares, prices, and estimated values.

APGE Key Metrics

Key financial metrics for APGE
Metric	Value
Price	$81.49
Market Cap	$5.94B
P/E Ratio	-19.12
EPS	$-4.22
Dividend Yield	0.00%
52-Week High	$95.32
52-Week Low	$26.20
Volume	382
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-255.84M
Gross Margin	0.00%

Recent APGE Insider Trades

HENDERSON MICHAEL THOMAS sold 18.66K (~$1.53M) on May 13, 2026.
HENDERSON MICHAEL THOMAS sold 1.34K (~$110.74K) on May 13, 2026.
Dambkowski Carl sold 3.70K (~$310.50K) on May 6, 2026.
Dambkowski Carl sold 1.80K (~$152.28K) on May 6, 2026.
Henderson Jane sold 811 (~$65.71K) on May 1, 2026.

Latest APGE News

Apogee Therapeutics rises after Q1 2026 results and pipeline update issued May 11 — May 11, 2026
Apogee’s Zumilokibart Achieves 85% Week 16 Maintenance at Six-Month Dosing, Secures $403M — May 11, 2026
Apogee Therapeutics climbs on new Buy initiation ahead of key Q2 dermatitis readout — May 4, 2026
Apogee Therapeutics slides as recent $350M equity offering overhang weighs on shares — Apr 29, 2026
Apogee Therapeutics slips as recent $350M follow-on offering overhang weighs on shares — Apr 26, 2026

APGE Analyst Consensus

15 analysts cover APGE: 0 strong buy, 13 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $122.25.

Common questions about APGE

Who is trading APGE stock inside the company?: Recent APGE insider activity includes HENDERSON MICHAEL THOMAS sold 18.66K, HENDERSON MICHAEL THOMAS sold 1.34K, Dambkowski Carl sold 3.70K, Dambkowski Carl sold 1.80K, and Henderson Jane sold 811. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for APGE?: Yes. Rallies tracks APGE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is APGE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for APGE. It does not provide personalized investment advice.